Applied NeuroSolutions, Inc. to Present at OneMedPlace Finance Forum for Emerging Healthcare and Life Science Companies

VERNON HILLS, IL--(Marketwire - January 05, 2010) - Applied NeuroSolutions, Inc. (OTCBB: APSN) (www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced that Craig S. Taylor, Ph.D., its President and Chief Executive Officer, will present an overview of the Company at the OneMedPlace Finance Forum. Dr. Taylor's presentation will be on Tuesday, January 12, 2010 at 1:45 p.m. Pacific Time at the Sir Francis Drake Hotel in San Francisco.

Dr. Taylor will provide an overview of Applied NeuroSolutions, Inc., including its Alzheimer's disease drug development collaboration with Eli Lilly and Company, and its AD diagnostic programs.

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTCBB: APSN) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progression of AD. For its diagnostic pipeline, Applied NeuroSolutions is focused on both serum and cerebrospinal fluid (CSF) tests to detect AD at a very early stage. The CSF based P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect AD. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be nearly 35 million patients. For more information, visit www.AppliedNeuroSolutions.com

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.AppliedNeuroSolutions.com, and review the company's filings with the Securities and Exchange Commission.